Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors

Phase 1

Completed

Conditions: Haemophilia B
Haemophilia B With Inhibitors
Haemophilia A
Congenital Bleeding Disorder
Haemophilia A With Inhibitors

Interventions: Drug: eptacog alfa (activated)

First Posted Date: 2013-09-25

Last Posted Date: 2014-11-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 6

Registration Number: NCT01949792

GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Behavioral: No treatment given
Behavioral: survey

First Posted Date: 2013-09-25

Last Posted Date: 2017-04-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1800

Registration Number: NCT01950650

Locations: 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom

GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Behavioral: No treatment given
Behavioral: survey

First Posted Date: 2013-09-25

Last Posted Date: 2017-01-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 4000

Registration Number: NCT01950637

Locations: 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom

A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy
Growth Disorder

Interventions: Drug: Genotropin Pen®
Drug: Norditropin® FlexPro® pen

First Posted Date: 2013-09-16

Last Posted Date: 2015-03-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 32

Registration Number: NCT01943084

Locations: 🇺🇸
Novo Nordisk Clinical Trial Call Center, Overland Park, Kansas, United States

A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart

First Posted Date: 2013-09-04

Last Posted Date: 2018-12-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 50

Registration Number: NCT01934712

Locations: 🇯🇵
Novo Nordisk Investigational Site, Fukuoka, Japan

A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Indonesia

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Other: No treatment given

First Posted Date: 2013-09-04

Last Posted Date: 2014-05-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1862

Registration Number: NCT01934686

A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Malaysia

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Other: No treatment given

First Posted Date: 2013-09-04

Last Posted Date: 2014-12-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1668

Registration Number: NCT01934673

A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in a Tablet Formulation With Three Different Coatings in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: insulin 338 (GIPET I)

First Posted Date: 2013-08-29

Last Posted Date: 2014-01-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 45

Registration Number: NCT01931137

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: sitagliptin
Drug: semaglutide
Drug: placebo

First Posted Date: 2013-08-28

Last Posted Date: 2019-06-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1231

Registration Number: NCT01930188

Locations: 🇺🇦
Novo Nordisk Investigational Site, Zaporizhia, Ukraine

Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

Phase 3

Completed

Conditions: Genetic Disorder
Noonan Syndrome

Interventions: Drug: somatropin

First Posted Date: 2013-08-23

Last Posted Date: 2020-08-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 51

Registration Number: NCT01927861

Locations: 🇯🇵
Novo Nordisk Investigational Site, Zentsuji, Kagawa, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy